Diabetes, Vol 49, Issue 6 969-974, Copyright © 2000 by American Diabetes Association

ARTICLES

Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes

JN Clore, J Stillman and H Sugerman
Department of Internal Medicine, Virginia Commonwealth University, Richmond 23298, USA. clore@hsc.vcu.edu

Despite the effects of hyperinsulinemia and hyperglycemia, 2 factors known to inhibit endogenous glucose production (EGP) in nondiabetic subjects, increased EGP is a consistent feature of type 2 diabetes. Recent studies have suggested that increased glucose-6-phosphatase (G6Pase) and/or decreased glucokinase (GK) may explain the increase in EGP. However, no studies to date have clearly established this relationship in type 2 diabetes. The present studies were designed to determine rates of EGP and the activities of G6Pase and GK in obese patients scheduled for gastric bypass surgery. The study group consisted of 14 obese nondiabetic subjects and 13 patients with type 2 diabetes (BMI 53.7 +/- 2.4 vs. 50.1 +/- 1.6 kg/m2). Rates of EGP were determined after an overnight fast with a 4-h infusion of [6,6]-D-glucose, and they were significantly higher in the type 2 diabetic patients (85.9 +/- 10.0 vs. 137.8 +/- 14.4 mg x m(-2) x min(-1), P < 0.001) despite greater plasma glucose (5.1 +/- 0.1 vs. 12.0 +/- 1.1 mmol/l) and similar insulin concentrations (130.8 +/- 19.8 vs. 112.8 +/- 16.2 pmol/l, NS). Moreover, resistance to insulin-induced suppression of EGP was observed in the patients with type 2 diabetes when insulin concentrations were increased from approximately 120 to 180 pmol/l. Hepatic G6Pase activity determined from freshly isolated microsomes was significantly increased in the type 2 diabetic patients compared with the obese control subjects (0.16 +/- 0.02 vs. 0.09 +/- 0.01 micromol x min(-1) x mg(-1) protein, P < 0.02), whereas levels of GK were decreased (1.20 +/- 0.16 vs. 2.01 +/- 0.01 micromol x min(-1) x mg(-1) protein, P < 0.01). Net flux through G6Pase was significantly increased in type 2 diabetic patients (P < 0.01). We conclude that increased EGP is mediated in part by increased G6Pase flux in type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Gautier-Stein, C. Zitoun, E. Lalli, G. Mithieux, and F. Rajas Transcriptional Regulation of the Glucose-6-phosphatase Gene by cAMP/Vasoactive Intestinal Peptide in the Intestine: ROLE OF HNF4{alpha}, CREM, HNF1{alpha}, and C/EBP{alpha} J. Biol. Chem., October 20, 2006; 281(42): 31268 - 31278. [Abstract] [Full Text] [PDF]

				M C Salgado, I Meton, M Egea, and I V Baanante Transcriptional regulation of glucose-6-phosphatase catalytic subunit promoter by insulin and glucose in the carnivorous fish, Sparus aurata J. Mol. Endocrinol., December 1, 2004; 33(3): 783 - 795. [Abstract] [Full Text] [PDF]

				C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]

				J. N. Clore, J. S. Stillman, J. Li, S. J. D. O'Keefe, and J. R. Levy Differential effect of saturated and polyunsaturated fatty acids on hepatic glucose metabolism in humans Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E358 - E365. [Abstract] [Full Text] [PDF]

				M. Hawkins, J. Tonelli, P. Kishore, D. Stein, E. Ragucci, A. Gitig, and K. Reddy Contribution of Elevated Free Fatty Acid Levels to the Lack of Glucose Effectiveness in Type 2 Diabetes Diabetes, November 1, 2003; 52(11): 2748 - 2758. [Abstract] [Full Text] [PDF]

				M. Hawkins, I. Gabriely, R. Wozniak, K. Reddy, L. Rossetti, and H. Shamoon Glycemic Control Determines Hepatic and Peripheral Glucose Effectiveness in Type 2 Diabetic Subjects Diabetes, July 1, 2002; 51(7): 2179 - 2189. [Abstract] [Full Text] [PDF]

				F. Rajas, A. Gautier, I. Bady, S. Montano, and G. Mithieux Polyunsaturated Fatty Acyl Coenzyme A Suppress the Glucose-6-phosphatase Promoter Activity by Modulating the DNA Binding of Hepatocyte Nuclear Factor 4alpha J. Biol. Chem., May 3, 2002; 277(18): 15736 - 15744. [Abstract] [Full Text] [PDF]

				M. Hawkins, I. Gabriely, R. Wozniak, C. Vilcu, H. Shamoon, and L. Rossetti Fructose Improves the Ability of Hyperglycemia Per Se to Regulate Glucose Production in Type 2 Diabetes Diabetes, March 1, 2002; 51(3): 606 - 614. [Abstract] [Full Text] [PDF]

				G. Mithieux, L. Guignot, J.-C. Bordet, and N. Wiernsperger Intrahepatic Mechanisms Underlying the Effect of Metformin in Decreasing Basal Glucose Production in Rats Fed a High-Fat Diet Diabetes, January 1, 2002; 51(1): 139 - 143. [Abstract] [Full Text] [PDF]

				T. H. van Dijk, F. H. van der Sluijs, C. H. Wiegman, J. F. W. Baller, L. A. Gustafson, H.-J. Burger, A. W. Herling, F. Kuipers, A. J. Meijer, and D.-J. Reijngoud Acute Inhibition of Hepatic Glucose-6-phosphatase Does Not Affect Gluconeogenesis but Directs Gluconeogenic Flux toward Glycogen in Fasted Rats. A PHARMACOLOGICAL STUDY WITH THE CHLOROGENIC ACID DERIVATIVE S4048 J. Biol. Chem., July 6, 2001; 276(28): 25727 - 25735. [Abstract] [Full Text] [PDF]

				M. Taouis, C. Dagou, C. Ster, G. Durand, M. Pinault, and J. Delarue N-3 Polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle Am J Physiol Endocrinol Metab, March 1, 2002; 282(3): E664 - E671. [Abstract] [Full Text] [PDF]